Curetis IPO

Holzgerlingen, Germany, November 10, 2015 — Curetis N.V.^[1] (the “Company” and, together with Curetis AG, “Curetis“), a developer of next-level molecular diagnostic solutions, today announces the completion of its initial public offering, which was launched on October 28, 2015 (the “IPO” or the “Offering“). The listing of and first trading of all of Curetis’ shares (the “Shares“) (on an “as-if-and-when-issued” basis) on Euronext in Amsterdam and Euronext in Brussels is expected to commence on November 11, 2015 (the “First Trading Date“) under the ticker symbol “CURE”.

Highlights of the Offering

• The final offer price for the Offering is set at EUR 10.00 (the “Offer Price“), corresponding to market capitalization of the Company at listing of approximately EUR 151 million (prior to the exercise of the Over-allotment Option).
• Total number of ordinary Shares issued in the Offering amounts to 4,000,000 new shares (the “New Shares“) (representing approximately 26.5% of the Shares, prior to the exercise of the Over-allotment Option).
• In addition, an Over-allotment Option to subscribe to up to 600,000 additional newly issued Shares (the “Additional Shares“), equivalent to up to 15% of the total number of the New Shares) at the Offer Price has been granted by the Company to RBC Capital Markets, as Sole Global Coordinator, on behalf of the Underwriters (the “Over-allotment Option“, and the Additional Shares together with the New Shares are referred to as the “Offer Shares“). The Over-allotment Option will be exercisable for a period of 30 calendar days following the First Trading Date.
• If the Over-allotment Option is exercised in full, the total number of Offer Shares will represent approximately 29.3% of the Shares and the approximate market capitalization of Curetis will be EUR 157 million (at the Offer Price). The Company will announce if and when the Over-allotment Option is exercised.
• Delivery of the Offer Shares, closing and settlement of the Offering and the start of unconditional trading in the Shares are expected to take place on November 13, 2015.

“We are very pleased that we could attract a significant number of renowned institutional investors in our IPO,” said Oliver Schacht, PhD, CEO of Curetis. “The success of the transaction demonstrates that the capital markets acknowledge the need for diagnostics such as our Unyvero solution, which are addressing infectious diseases and antibiotic resistances.”

Further details on the Offering

The Offering consists of a public offering in Germany to retail and institutional investors and a private placement to certain institutional and other eligible investors in various other jurisdictions.

Curetis AG’s existing shareholders have agreed to lock-up provisions for a period of 365 days of which the first 180 days is a hard-lock period during which the restrictions under the lock-up may not be waived by the Joint Bookrunners (acting on behalf of the Underwriters). The Company, its managing directors and Curetis AG’s current and former employees have also agreed to lock-up provisions for a period of 365 days. The restrictions under the lock-up provisions applicable to the Company’s managing directors and Curetis AG’s current and former employees may not be waived during their term. All lock-up arrangements are subject to customary carve-outs.

RBC Capital Markets acted as Sole Global Coordinator for the Offering. RBC Capital Markets and Bank Degroof Petercam together acted as Joint Bookrunners for the Offering. ICF Bank AG acted as Joint Lead Manager for the Offering. The Joint Bookrunners and the Joint Lead Manager together acted as Underwriters for the Offering. ICF Bank AG acted as Retail Coordinator for the Offering of Offer Shares to eligible retail investors in Germany. RBC Capital Markets will also be acting as Stabilisation Manager on behalf of the Underwriters.

Availability of the prospectus and pricing statement

The Offering has been made solely by means of a prospectus. Copies of the prospectus may, subject to applicable securities law restrictions, be obtained from the website of Curetis (www.curetis.com).

This press release also serves as the pricing statement in relation to the Offering and has been filed with the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten). This press release is also available on Curetis’ website (www.curetis.com).

Contact details
Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com
www.curetis.com – www.unyvero.com

Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised EUR 40 million in an IPO on Euronext Amsterdam and Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.

For further information, please visit www.curetis.com.